Low telomerase activity: Possible role in the progression of human medullary thyroid carcinoma

European Journal of Cancer

Volumn 44, Issue 6, 2008, Pages 866-875

  Stadler, Guido ^a   Wieser, Matthias ^a   Streubel, Berthold ^b   Stift, Anton ^b   Friedl, Josef ^b   Gnant, Michael ^b   Niederle, Bruno ^b   Beham, Alfred ^c   Katinger, Hermann ^a   Pfragner, Roswitha ^c   Grillari, Johannes ^a   Voglauer, Regina ^a  

^a UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

hTERT; Immortalisation; Medullary thyroid carcinoma; MST 312; Telomerase activity; Telomerase inhibitor

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CELL COUNT; CELL DIVISION; CELL GROWTH; CELL IMMORTALIZATION; CELL POPULATION; CELL STRAIN; CELL STRAIN HEK293; ENZYME ACTIVITY; ENZYME REACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INDUCED MUTATION; LIFESPAN; PHENOTYPE; PRIORITY JOURNAL; TELOMERE; THYROID MEDULLARY CARCINOMA;

CARCINOMA, MEDULLARY; DISEASE PROGRESSION; HUMANS; NEOPLASM PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TELOMERASE; TELOMERE; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 41849093688     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.12.014     Document Type: Article

References (49)

1. Hayflick L., and Moorhead P.S. The serial cultivation of human diploid cell strains. Exp Cell Res 25 (1961) 585-621
2. Olovnikov A.M. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol 41 (1973) 181-190
3. d'Adda di Fagagna F., Reaper P.M., Clay-Farrace L., et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426 (2003) 194-198 Epub 2003 Nov 5
4. Greider C.W., and Blackburn E.H. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 43 (1985) 405-413
5. Hiyama E., and Hiyama K. Telomerase as tumor marker. Cancer Lett 194 (2003) 221-233
6. Bryan T.M., Englezou A., Gupta J., Bacchetti S., and Reddel R.R. Telomere elongation in immortal human cells without detectable telomerase activity. Embo J 14 (1995) 4240-4248
7. Reddel R.R. Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett 194 (2003) 155-162
8. Brachner A., Sasgary S., Pirker C., et al. Telomerase- and alternative telomere lengthening-independent telomere stabilization in a metastasis-derived human non-small cell lung cancer cell line: effect of ectopic hTERT. Cancer Res 66 (2006) 3584-3592
9. Cerone M.A., Autexier C., Londono-Vallejo J.A., and Bacchetti S. A human cell line that maintains telomeres in the absence of telomerase and of key markers of ALT. Oncogene (2005)
10. Cerone M.A., Londono-Vallejo J.A., and Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 10 (2001) 1945-1952
11. Fasching C.L., Bower K., and Reddel R.R. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res 65 (2005) 2722-2729
12. Perrem K., Colgin L.M., Neumann A.A., Yeager T.R., and Reddel R.R. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 21 (2001) 3862-3875
13. Johnson J.E., Varkonyi R.J., Schwalm J., et al. Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 11 (2005) 5347-5355
14. Matthews P., Jones C.J., Skinner J., Haughton M., de Micco C., and Wynford-Thomas D. Telomerase activity and telomere length in thyroid neoplasia: biological and clinical implications. J Pathol 194 (2001) 183-193
15. Pfragner R., Hofler H., Behmel A., Ingolic E., and Walser V. Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 50 (1990) 4160-4166
16. Pfragner R., Wirnsberger G., Behmel A., et al. New continuous cell line from human medullary thyroid carcinoma: SINJ. Phenotypic analysis and in vivo carcinogenesis. Int J Oncol 2 (1993) 831-836
17. Pfragner R., Wirnsberger G.H., Ingolic E., and Niederle B. Medullary thyroid carcinomas in cell culture-models for future therapies. Wien Klin Wochenschr 114 (2002) 279-283
18. Lerma E., and Mora J. Telomerase activity in "suspicious" thyroid cytology. Cancer 15 (2005) 15
19. Mora J., and Lerma E. Telomerase activity in thyroid fine needle aspirates. Acta Cytol 48 (2004) 818-824
20. Suzuki S., Fukushima T., Ami H., Onogi H., Nakamura I., and Takenoshita S. New attempt of preoperative differential diagnosis of thyroid neoplasms by telomerase activity measurement. Oncol Rep 9 (2002) 539-544
21. Kammori M., Takubo K., Nakamura K., et al. Telomerase activity and telomere length in benign and malignant human thyroid tissues. Cancer Lett 159 (2000) 175-181
22. Lo C.Y., Lam K.Y., Chan K.T., and Luk J.M. Telomerase activity in thyroid malignancy. Thyroid 9 (1999) 1215-1220
23. Aogi K., Kitahara K., Urquidi V., Tarin D., and Goodison S. Comparison of telomerase and CD44 expression as diagnostic tumor markers in lesions of the thyroid. Clin Cancer Res 5 (1999) 2790-2797
24. Haugen B.R., Nawaz S., Markham N., et al. Telomerase activity in benign and malignant thyroid tumors. Thyroid 7 (1997) 337-342
25. Yashima K., Vuitch F., Gazdar A.F., and Fahey III T.J. Telomerase activity in benign and malignant thyroid diseases. Surgery 122 (1997) 1141-1145 discussion 1145-6
26. Bockhorn M., Frilling A., Clauer U., Hertl M., and Broelsch C.E. Telomerase activity in neuroendocrine tumors. Int J Surg Investig 2 (2000) 219-225
27. Stadler G., Wieser M., Steindl F., et al. Development of standardized cell culture conditions for tumor cells with potential clinical application. Cytotherapy 9 (2007) 488-498
28. Lee H.W., Blasco M.A., Gottlieb GJ Horner J.W., Greider C.W., and DePinho R.A. Essential role of mouse telomerase in highly proliferative organs. Nature 392 (1998) 569-574
29. Voglauer R., Grillari J., Fortschegger K., et al. Establishment of human fibroma cell lines from a MEN1 patient by introduction of either hTERT or SV40 early region. Int J Oncol 26 (2005) 961-970
30. Voglauer R., Chang M.W., Dampier B., et al. SNEV overexpression extends the life span of human endothelial cells. Exp Cell Res 312 (2006) 746-759
31. Maser R.S., and DePinho R.A. Connecting chromosomes, crisis, and cancer. Science 297 (2002) 565-569
32. Shay J.W., and Wright W.E. Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp Cell Res 184 (1989) 109-118
33. Vaziri H., and Benchimol S. From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. Exp Gerontol 31 (1996) 295-301
34. Rubelj I., and Pereira-Smith O.M. SV40-transformed human cells in crisis exhibit changes that occur in normal cellular senescence. Exp Cell Res 211 (1994) 82-89
35. Halvorsen T.L., Leibowitz G., and Levine F. Telomerase activity is sufficient to allow transformed cells to escape from crisis. Mol Cell Biol 19 (1999) 1864-1870
36. Shay J.W., Van Der Haegen B.A., Ying Y., and Wright W.E. The frequency of immortalization of human fibroblasts and mammary epithelial cells transfected with SV40 large T-antigen. Exp Cell Res 209 (1993) 45-52
37. Herbert B.S., Wright A.C., Passons C.M., et al. Effects of chemopreventive and antitelomerase agents on the spontaneous immortalization of breast epithelial cells. J Natl Cancer Inst 93 (2001) 39-45
38. Pelengaris S., Khan M., and Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2 (2002) 764-776
39. Seimiya H., Oh-hara T., Suzuki T., et al. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 1 (2002) 657-665
40. Seimiya H., Muramatsu Y., Ohishi T., and Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 7 (2005) 25-37
41. Seger Y.R., Garcia-Cao M., Piccinin S., et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2 (2002) 401-413
42. Gordon K.E., Ireland H., Roberts M., et al. High levels of telomere dysfunction bestow a selective disadvantage during the progression of human oral squamous cell carcinoma. Cancer Res 63 (2003) 458-467
43. Holm R., and Nesland J.M. Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland. J Pathol 172 (1994) 267-272
44. Coxon A.B., Ward J.M., Geradts J., Otterson G.A., Zajac-Kaye M., and Kaye F.J. RET cooperates with RB/p53 inactivation in a somatic multi-step model for murine thyroid cancer. Oncogene 17 (1998) 1625-1628
45. Wang D.G., Liu W.H., Johnston C.F., Sloan J.M., and Buchanan K.D. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis. Am J Pathol 152 (1998) 1407-1413
46. Yoshida A., Nakamura Y., Imada T., Asaga T., Shimizu A., and Harada M. Apoptosis and proliferative activity in thyroid tumors. Surg Today 29 (1999) 204-208
47. Sharma G.G., Gupta A., Wang H., et al. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 22 (2003) 131-146
48. Lu C., Fu W., and Mattson M.P. Telomerase protects developing neurons against DNA damage-induced cell death. Brain Res Dev Brain Res 131 (2001) 167-171
49. Wu K.J., Grandori C., Amacker M., et al. Direct activation of TERT transcription by c-MYC. Nat Genet 21 (1999) 220-224